Castle Biosciences Reports Second Quarter 2019 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. CVS

Go back to Castle Biosciences Reports Second Quarter 2019 Results

Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 31c, Revenues Beat

September 3, 2019 4:09 PM EDT

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($1.05), $0.31 better than the analyst estimate of ($1.36). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $7.48 million.

Q2 2019 DecisionDx-Melanoma test report volume increased 27% compared to Q2 2018Q2 2019 recognized revenues increased to $10.7 million, up from $4.0 million in Q2 2018Q2 2019 gross margin increased to 81%, up from 67% in Q2 2018

We are pleased with our strong second quarter performance, including our 27% year-over-year growth in DecisionDx-Melanoma test report volume, which we believe was largely driven by our successful first quarter 2019 commercial... More